Nov 10 (Reuters) – A U.S. jury on Wednesday ordered Bayer AG (BAYGn.DE) to pay $62 million to college students and others who say they had been uncovered to poisonous chemical substances made by the corporate’s predecessor, Monsanto Co, in a school building in Washington state.
The decision was the second in opposition to Bayer over polychlorinated biphenyls, or PCBs, on the Sky Valley Schooling Heart in Monroe, Washington.
A trial involving three lecturers resulted in a $185 million verdict in July, together with $135 million in punitive damages, which Bayer is interesting.
Bayer stated it might problem the decision by means of post-trial motions, and that “undisputed evidence in this case does not support the conclusions that plaintiffs were exposed to unsafe levels of PCBs” on the school.
Practically 200 individuals, together with college students, mother and father and employees, have sued Bayer over the alleged contamination ensuing from publicity to PCBs present in fluorescent mild ballasts at Sky Valley, and 19 extra trials are scheduled.
The plaintiffs assert they suffered well being issues, together with bronchial asthma and cognitive impairment. Bayer has stated the lighting parts had been produced many years in the past by Monsanto clients and put in within the Nineteen Sixties.
Wednesday’s verdict, which incorporates $35 million in punitive damages, adopted a trial involving eight plaintiffs: 4 college students, three mother and father and a band member who practiced on the school.
PCBs had been as soon as used extensively to insulate electrical gear, in addition to in caulking, flooring end and paint. The U.S. authorities outlawed them in 1979 after they had been linked to most cancers and different well being issues.
Monsanto, which Bayer purchased for $63 billion in 2018, produced PCBs from 1935 to 1977.
In December, a federal choose rejected Bayer’s proposed $648 million settlement of separate class-action litigation by cities and different claimants over wastewater contaminated with PCBs made by Monsanto. The corporate has stated it expects a revised model of the deal to be authorised.
Reporting By Brendan Pierson in New York
Modifying by Chris Reese and Howard Goller
Our Requirements: The Thomson Reuters Trust Principles.